Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2016 Oct 23

PMID 27770215

Citations 83

Authors

George J Greene

Greg Swann

Angela J Fought

Alex Carballo-Dieguez

Thomas J Hope

Patrick F Kiser

Brian Mustanski

Richard T DAquila

Affiliations

Soon will be listed here.

Abstract

HIV prevention method preferences were evaluated among 512 U.S. men who have sex with men (MSM; median age: 22 years). Approximately 90 % consistently preferred one option across pairwise comparisons of condoms, daily oral pre-exposure prophylaxis (PrEP), and long-acting PrEP delivered via either an injectable or one of two types of PrEP implants differing in visibility. Condoms were most frequently preferred (33.8 %), followed by non-visible implants (21.5 %), and oral PrEP (17.0 %); HIV risk was reported by more choosing implants. In a follow-up question comparing the four PrEP options only, daily oral pills and non-visible implants were most frequently preferred (35.5 and 34.3 %, respectively), followed by injections (25.2 %) and visible implants (4.3 %). An inductive, open-coding approach determined that convenience, duration of protection, and privacy were the most commonly cited reasons for a PrEP method choice, and associated with self-report of HIV risk. Tailoring PrEP product development to privacy and other concerns important to those at highest HIV risk may improve HIV prevention.

Citing Articles

Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model.

Fraysse J, Anderson S, Smith J, Matthews D, Sarkar S, de Aragao F PLoS One. 2025; 20(1):e0312369.

PMID: 39787101 PMC: 11717278. DOI: 10.1371/journal.pone.0312369.

Lower PrEP Retention among Young and Black Clients Accessing PrEP at a Cluster of Safety Net Clinics for Gay and Bisexual Men.

Agarwal H, Erwin M, Lyles S, Esposito M, Ahsan Z J Int Assoc Provid AIDS Care. 2024; 23:23259582241275857.

PMID: 39219500 PMC: 11375660. DOI: 10.1177/23259582241275857.

Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subcutaneous implant.

Kim H, Zhang L, Hendrix C, Haberer J, von Kleist M CPT Pharmacometrics Syst Pharmacol. 2024; 13(10):1693-1706.

PMID: 39164932 PMC: 11494919. DOI: 10.1002/psp4.13212.

Behind Prep Decisions: Understanding User Patterns and Discontinuation Factors in Real-World.

Braz Junior R, Cesar G, Amianti C, Bandeira L, Da Silva A, Motta-Castro A AIDS Behav. 2024; 28(9):2979-2989.

PMID: 38825651 DOI: 10.1007/s10461-024-04383-2.

Perspectives on Injectable HIV Pre-Exposure Prophylaxis: A Qualitative Study of Health Care Providers in the United States.

Bleasdale J, McCole M, Cole K, Hequembourg A, Morse G, Przybyla S AIDS Patient Care STDS. 2024; 38(4):177-184.

PMID: 38656214 PMC: 11236283. DOI: 10.1089/apc.2024.0001.

References

Margolis D, Boffito M . Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS. 2015; 10(4):246-52. PMC: 5638428. DOI: 10.1097/COH.0000000000000169. View

Voetsch A, Heffelfinger J, Begley E, Jafa-Bhushan K, Sullivan P . Knowledge and use of preexposure and postexposure prophylaxis among attendees of Minority Gay Pride events, 2005 through 2006. J Acquir Immune Defic Syndr. 2007; 46(3):378-80. DOI: 10.1097/QAI.0b013e3181576874. View

Boffito M, Jackson A, Owen A, Becker S . New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs. 2013; 74(1):7-13. DOI: 10.1007/s40265-013-0163-7. View

Golub S, Kowalczyk W, Weinberger C, Parsons J . Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010; 54(5):548-55. PMC: 2908204. DOI: 10.1097/QAI.0b013e3181e19a54. View

McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

Bauermeister J, Meanley S, Pingel E, Soler J, Harper G . PrEP awareness and perceived barriers among single young men who have sex with men. Curr HIV Res. 2014; 11(7):520-7. PMC: 4152728. DOI: 10.2174/1570162x12666140129100411. View

Mimiaga M, Case P, Johnson C, Safren S, Mayer K . Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009; 50(1):77-83. PMC: 2659469. DOI: 10.1097/QAI.0b013e31818d5a27. View

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

Palanee-Phillips T, Schwartz K, Brown E, Govender V, Mgodi N, Kiweewa F . Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. PLoS One. 2015; 10(6):e0128857. PMC: 4489588. DOI: 10.1371/journal.pone.0128857. View

10.

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

11.

Anderson P, Glidden D, Liu A, Buchbinder S, Lama J, Guanira J . Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151):151ra125. PMC: 3721979. DOI: 10.1126/scitranslmed.3004006. View

12.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

13.

Mansergh G, Koblin B, Sullivan P . Challenges for HIV pre-exposure prophylaxis among men who have sex with men in the United States. PLoS Med. 2012; 9(8):e1001286. PMC: 3424255. DOI: 10.1371/journal.pmed.1001286. View

14.

Jackson A, McGowan I . Long-acting rilpivirine for HIV prevention. Curr Opin HIV AIDS. 2015; 10(4):253-7. DOI: 10.1097/COH.0000000000000160. View

15.

Amico K, Stirratt M . Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014; 59 Suppl 1:S55-60. PMC: 4060253. DOI: 10.1093/cid/ciu266. View

16.

Aghaizu A, Mercey D, Copas A, Johnson A, Hart G, Nardone A . Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2012; 89(3):207-11. DOI: 10.1136/sextrans-2012-050648. View

17.

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-90. DOI: 10.1016/S0140-6736(13)61127-7. View

18.

Saberi P, Gamarel K, Neilands T, Comfort M, Sheon N, Darbes L . Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS One. 2012; 7(11):e50061. PMC: 3498189. DOI: 10.1371/journal.pone.0050061. View

19.

Dolezal C, Frasca T, Giguere R, Ibitoye M, Cranston R, Febo I . Awareness of Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) Is Low but Interest Is High Among Men Engaging in Condomless Anal Sex With Men in Boston, Pittsburgh, and San Juan. AIDS Educ Prev. 2015; 27(4):289-97. PMC: 4610145. DOI: 10.1521/aeap.2015.27.4.289. View

20.

Grov C . HIV risk and substance use in men who have sex with men surveyed in bathhouses, bars/clubs, and on Craigslist.org: venue of recruitment matters. AIDS Behav. 2011; 16(4):807-17. PMC: 5826651. DOI: 10.1007/s10461-011-9999-6. View